Patents Assigned to The Center for the Improvement of Human Functioning, Int'l., Inc.
  • Cancer treatment method
    Patent number: 6436411
    Abstract: Treatment of tumors, including their metastases, is described. Retrieved cytokines and other molecules from the growth medium of human monocytes stimulated ex vivo with gamma globulin, or other immune stimulators are employed for cancer therapy.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: August 20, 2002
    Assignee: The Center for the Improvement of Human Functioning, Int'l., Inc.
    Inventors: Neil H. Riordan, Hugh D. Riordan
  • Treatment of cancer using lipoic acid in combination with ascorbic acid
    Patent number: 6284786
    Abstract: Lipoic acid and/or its water soluble salt is used to treat cancer, alone or in combination with ascorbic acid (vitamin C). Alone or in combination, it was shown to be effective on in vitro tumors and mouse tumors. The agents can be administered safely, and have been used effectively in case studies.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: September 4, 2001
    Assignee: The Center for the Improvement of Human Functioning, Int'l., Inc.
    Inventors: Joseph J. Casciari, Neil H. Riordan
  • High molecular weight extracts of Convolvulus arvensis field (field bindweed)
    Patent number: 6083510
    Abstract: A purified bindweed extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed extract is prepared by removing toxic low molecular weight components of Convolvulus arvensis.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: July 4, 2000
    Assignee: The Center for the Improvement of Human Functioning, Int'l., Inc.
    Inventors: Xiaolong Meng, Hugh D. Riordan, Neil H. Riordan
  • Therapeutic method for the treatment of cancer
    Patent number: 5639787
    Abstract: A method of treating cancer in a patient by raising and maintaining the concentration of ascorbic acid, or ascorbate, in the patient's plasma to at least the level expected to be toxic to an in vitro culture of cells of the type of cancer being treated, the required plasma ascorbate levels being achieved and maintained using long term intravenous infusions of large amounts of ascorbate, with or without ascorbate cytotoxicity effectiveness enhancing or tumor site delivery and absorption enhancing agents.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: June 17, 1997
    Assignee: The Center for the Improvement of Human Functioning Int'l, Inc.
    Inventors: Neil H. Riordan, Hugh D. Riordan